The company announced it will use proceeds "to advance its product pipeline, including its lead program, custirsen, and 427, which is currently in clinical development as a treatment for prostate and bladder cancer, as well as for general corporate purposes".
Well, that explanation is good enough for me. Bringing 011 in prostate and lung to market, as well as 427 in prostate and bladder, will make this a multi billion dollar company. We also need some stability in the interim. I hope the growth of a stable investor base will accomplish this objective.
>Well, that explanation is good enough for me. Bringing 011 in prostate and lung to market, as well as 427 in prostate and bladder
Well. O11 is externally funded. 427 Prostate is externally funded. A P2 study for bladder wont cost a lot. So what are going to do with the rest of the $90M+? So I think they have something else in mind. The CC is next week. What are we going to hear? Couple more P2 studies for 427? A surprise? Buying full 427 or O11 rights from ISIS? Or was this just a normal precaution to keep the co going in case O11 fails?